Aspen welcomes conclusion to EU pricing probe
MLex Summary: Aspen has welcomed the end of an EU probe into the pricing of its cancer drugs, saying the payments it will have to make to customers for past prices...To view the full article, register now.
Already a subscriber? Click here to view full article